All In Biotech

BLA 761320 · Outlook Therapeutics, Inc.

Lytenava

Bevacizumab-Vikg · Single-Dose · Vascular Endothelial Growth Factor Inhibitor

Novel

CDER novel approval, Jul 24, 2026: To treat patients with neovascular (wet) age-related macular degeneration

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Jul 24, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,998

508 Phase 3, 455 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 29, 2026.

LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD). LYTENAVA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD) ( 1 ).

Mechanism: Bevacizumab is a human vascular endothelial growth factor (VEGF) inhibitor. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. LYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses endothelial cell proliferation, neovascularization, and vascular permeability. Inhibition of such activity targets a pathophysiologic process that contributes to vision loss.

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 24, 2026 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelLabelLetterReview
1 products under this application
  • LYTENAVA · BEVACIZUMAB-VIKG 1.25MG (0.05ML of 25MG/ML · VIAL, SINGLE-DOSE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bevacizumab" as an intervention, any sponsor and status, largest first.

All 2,998 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,932 on PubMed

Sponsor: Outlook Therapeutics, Inc.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.